Literature DB >> 32246168

Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab.

S R Cummings1,2, C McCulloch3.   

Abstract

Entities:  

Year:  2020        PMID： 32246168     DOI： 10.1007/s00198-020-05379-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  9 in total

Review 1.  Role of bone-forming agents in the management of osteoporosis.

Authors:  Michael R McClung
Journal:  Aging Clin Exp Res       Date:  2021-02-16       Impact factor: 3.636

Review 2.  Cardiovascular Safety and Effectiveness of Bisphosphonates: From Intervention Trials to Real-Life Data.

Authors:  Chiara Delli Poggi; Maria Fusaro; Maria Cristina Mereu; Maria Luisa Brandi; Luisella Cianferotti
Journal:  Nutrients       Date:  2022-06-07       Impact factor: 6.706

Review 3.  Drug discovery of sclerostin inhibitors.

Authors:  Sifan Yu; Dijie Li; Ning Zhang; Shuaijian Ni; Meiheng Sun; Luyao Wang; Huan Xiao; Dingdong Liu; Jin Liu; Yuanyuan Yu; Zongkang Zhang; Samuel Tin Yui Yeung; Shu Zhang; Aiping Lu; Zhenlin Zhang; Baoting Zhang; Ge Zhang
Journal:  Acta Pharm Sin B       Date:  2022-01-21       Impact factor: 14.903

Review 4.  Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?

Authors:  Felicia Cosman; David W Dempster
Journal:  Curr Osteoporos Rep       Date:  2021-02-26       Impact factor: 5.096

Review 5.  Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs.

Authors:  N R Fuggle; C Cooper; N C Harvey; N Al-Daghri; M-L Brandi; O Bruyere; A Cano; E M Dennison; A Diez-Perez; J-M Kaufman; S Palacios; D Prieto-Alhambra; S Rozenberg; T Thomas; F Tremollieres; R Rizzoli; J A Kanis; J Y Reginster
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

Review 6.  Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk.

Authors:  Sian Yik Lim
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

Review 7.  Anabolic treatments for osteoporosis in postmenopausal women.

Authors:  Neelam Hassan; Celia L Gregson; Jon H Tobias
Journal:  Fac Rev       Date:  2021-05-05

8.  Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.

Authors:  Felicia Cosman; Linda R Peterson; Dwight A Towler; Bruce Mitlak; Yamei Wang; Steven R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

Review 9.  Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies.

Authors:  Alexander J Rodríguez; Bo Abrahamsen
Journal:  JBMR Plus       Date:  2021-06-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.